Keywords: Deuterium, Cancer, molecular imaging; preclinical
Motivation: Systemic deuterated water administration leads to higher cellular deuterium content and imaging contrast between proliferating tumor and healthy tissue.
Goal(s): We previously showed excellent deuterium imaging contrast between xenografts and muscle at 9.4T with 7 days of 8% deuterated water in total body water (TBW), v/v. Clinical translation of this approach would benefit from lower TBW goals given volume, cost, and ease.
Approach: We tested lower TBW deuterium levels and shorter duration of labeling in a xenograft model at 7T.
Results: We demonstrate deuterium imaging contrast between tumors and muscle at 2 and 4% TBW without significant benefit from longer duration of labeling.
Impact: Systemic administration of deuterated water can preferentially label tumors for dMRI. This approach has been tested in animal models, while clinical implementation in oncology warrants lower doses and shorter labeling durations. Thus, we tested clinically relevant deuterated water labeling schemas.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords